Celmatix and Reproductive Medicine Associates of New York Announce Landmark Study Correlating Optimal Hormone Stimulation with Embryo Quality

Large-scale study announced at the American Society for
Reproductive Medicine meeting is reassuring news for individuals
utilizing IVF 

BALTIMORE–(BUSINESS WIRE)–From ASRM Annual Meeting – Celmatix,
a personalized medicine company focused on fertility and women’s health,
and Reproductive Medicine Associates of New York (RMA-NY), a
Manhattan-based fertility center with an extensive history of providing
personalized care for patients requiring reproductive assistance,
announced today the results of a large-scale study on the effect of
hormone-stimulation, routinely used during in vitro fertilization (IVF)
procedures, on embryo quality. The results were presented at the
American Society for Reproductive Medicine 2015 Annual Meeting. The
study was conducted in response to ongoing controversy in the field
whether treatment protocols involving minimal or maximal hormone
stimulation dosages lead to better embryo quality and outcomes from IVF
procedures.

The study, which analyzed data from over 13,000 IVF treatment cycles
undergone by 7,530 patients at RMA-NY, found that, for the majority of
women in the study, increasing hormone stimulation dosages did not
decrease embryo quality as measured by pre-implantation genetic
screening of embryos for chromosomal abnormalities. In contrast, they
found that the mother’s overall fertility potential, as a factor of age
and other clinical metrics, was the dominant driver of embryo quality.

“We hear from physicians in our network that patients undergoing IVF are
often concerned that hormone-stimulation could impact their embryo
quality,” explained Dr. Piraye Yurttas Beim, CEO and founder of
Celmatix. “For the first time, we can ask this question in a data-driven
way because thousands of patients have undergone pre-implantation
genetic screening of their embryos, and we can correlate the rates of
chromosomal abnormalities with metrics such as age and hormone
stimulation protocols. It was reassuring to see that most women who
required higher doses of hormone stimulation to achieve the optimal
number of embryos did not have their embryo quality negatively impacted
by these protocols. Our work underscores the importance of using
data-driven methods to identify the ideal dose that allows a woman to
maximize her chances of having a healthy baby through IVF.”

Dr. Alan Copperman, director of the Division of Reproductive
Endocrinology and Infertility at Mount Sinai Hospital and medical
director of RMA of New York, agreed, stating that, “The game has changed
now that we screen embryos for chromosomes prior to transfer. Optimal
stimulation is defined as not the amount of medications, but as the
right stimulation dosage and protocol to create a healthy embryo and a
healthy baby. I applaud Celmatix for using data to help our patients
reach success in their fertility journey.”

About Celmatix
Celmatix is a personalized medicine company
that uses big data and predictive analytics to help individuals who are
struggling to have a baby make informed decisions. Founded in 2009 and
based in New York City, Celmatix is disrupting the way women approach
their lifelong fertility journey by empowering them through science and
technology. The company’s flagship Polaris product, in use at top
fertility clinics across the country, is the world’s first analytics
platform for optimizing fertility. Celmatix also has an active research
and development program dedicated to decoding the genetic basis of
fertility potential. For more information, visit www.celmatix.com.

About Reproductive Medicine Associates of New York
Reproductive
Medicine Associates of New York (RMA of New York) is widely recognized
as a national and international leader in state-of-the-art reproductive
medicine. Led by an integrated team of doctors and scientists with
extensive reproductive endocrinology, fertility and urology experience
and training, RMA of New York consistently reports IVF success rates to
the Society for Assisted Reproductive Technology (SART) and the Center
for Disease Control and Prevention (CDC) and is internationally
recognized for achieving high success rates in the treatment of
infertility. RMA of New York maximizes access to care by helping
patients explore all insurance coverage and financing options available
for treatment. RMA of New York is sensitive to the needs of the LGBT
community, women choosing single or same-sex motherhood, as well as
women interested in elective fertility preservation. Headquartered in
midtown Manhattan, RMA of New York has patient care facilities
throughout New York City, as well as in Brooklyn, Garden City,
Westchester, and abroad in Mexico City. For more information, please
visit www.rmany.com.

Contacts

Brew Media
Michelle Kim, 310-464-6344
mkim@brewpr.com